Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady-state liraglutide 1.8?mg versus placebo on postprandial plasma lipid concentrations after 3?weeks of treatment in patients with type 2 diabetes mellitus (T2DM).
In a cross-over trial, patients with T2DM (n?=?20, 18-75?years, BMI 18.5-40?kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8?mg) and placebo. After each 3-week period, a standardized fat-rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC(0-8h)), apolipoprotein B48, non-esterified fatty acids, glycaemic responses and gastric emptying were assessed. ClinicalTrials.gov ID: NCT00993304.
Novo Nordisk A/S.
After 3?weeks, mean postprandial triglyceride (AUC(0-8h) liraglutide/placebo treatment-ratio 0.72, 95% CI [0.62-0.83], p?=?0.0004) and apolipoprotein B48 (AUC(0-8h) ratio 0.65 [0.58-0.73], p?